公开(公告)号：US20190144429A1

公开(公告)日：2019-05-16

申请号：US16261689

申请日：2019-01-30

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute ,  Gõran Mattias Wennerstål ,  James Robert Blinn ,  Neelu Kaila ,  James Richard Kiefer, JR. ,  Scot Richard Mente ,  Ravi G. Kurumbail ,  Marvin Jay Meyers ,  Atli Thorarensen ,  Li Xing ,  Christoph Wolfgang Zapf ,  Edouard Zamaratski ,  Andrew Christopher Flick ,  Peter Jones

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D403/04 ,  C07D487/04 ,  C07D471/04 ,  C07D417/14 ,  C07D413/04 ,  C07D407/14 ,  C07D401/04 ,  A61K31/5355 ,  A61K31/519 ,  A61K31/506 ,  A61K31/497 ,  A61K31/454

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

公开(公告)号：US11708360B2

公开(公告)日：2023-07-25

申请号：US17192968

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, Jr. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

CPC classification number: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/65583

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)




or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20180273504A1

公开(公告)日：2018-09-27

申请号：US15547228

申请日：2016-01-29

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute ,  Andrew Christopher Flick ,  Peter Jones ,  Neelu Kaila ,  Scot Richard Mente ,  John David Trzupek ,  Michael L. Vazquez ,  Goran Mattias Wennerstal ,  Li Xing ,  Edouard Zamaratski ,  Liying Zhang ,  Rayomand J. Unwalla

IPC: C07D401/04 ,  A61P29/00 ,  A61P37/06 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D401/04 ,  A61P29/00 ,  A61P37/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

公开(公告)号：US20240368144A1

公开(公告)日：2024-11-07

申请号：US18311266

申请日：2023-05-03

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, JR. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20210206757A1

公开(公告)日：2021-07-08

申请号：US17192968

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, JR. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US10426135B2

公开(公告)日：2019-10-01

申请号：US16268857

申请日：2019-02-06

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute ,  Andrew Christopher Flick ,  Peter Jones ,  Neelu Kaila ,  Scot Richard Mente ,  John David Trzupek ,  Michael L. Vazquez ,  Goran Mattias Wennerstal ,  Li Xing ,  Edouard Zamaratski ,  Liying Zhang ,  Rayomand Jal Unwalla

IPC: C07D401/02 ,  C07D401/10 ,  A61K31/437 ,  A61K31/4353 ,  A01K5/01 ,  B65D77/20 ,  B65D25/04 ,  B65D1/34 ,  A01K7/00 ,  A23K20/00 ,  A23K50/48 ,  B65D1/36 ,  B65D25/18 ,  B65D85/00

Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

公开(公告)号：US20200039960A1

公开(公告)日：2020-02-06

申请号：US16656702

申请日：2019-10-18

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute ,  Göran Mattias Wennerstål ,  James Robert Blinn ,  Neelu Kaila ,  James Richard Kiefer, Jr. ,  Scot Richard Mente ,  Ravi G. Kurumbail ,  Marvin Jay Meyers ,  Atli Thorarensen ,  Li Xing ,  Christoph Wolfgang Zapf ,  Edouard Zamaratski ,  Andrew Christopher Flick ,  Peter Jones

IPC: C07D401/14 ,  C07D413/14 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5355 ,  C07D407/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

公开(公告)号：US20190292157A1

公开(公告)日：2019-09-26

申请号：US16380256

申请日：2019-04-10

Applicant: Pfizer Inc.

Inventor： Agustin Casimiro-Garcia ,  Jeffrey Scott Condon ,  Andrew Christopher Flick ,  Ariamala Gopalsamy ,  Steven J. Kirincich ,  John Paul Mathias ,  Joseph Walter Strohbach ,  Jason Shaoyun Xiang ,  Li Huang Xing ,  Xiaolun Wang

IPC: C07D239/42 ,  A61P35/00 ,  A61P1/04 ,  A61P1/00 ,  C07D405/10 ,  A61K31/505 ,  C07D401/12 ,  C07D241/14 ,  C07D239/28 ,  C07D403/12

Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US10385036B2

公开(公告)日：2019-08-20

申请号：US15547228

申请日：2016-01-29

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute ,  Andrew Christopher Flick ,  Peter Jones ,  Neelu Kaila ,  Scot Richard Mente ,  John David Trzupek ,  Michael L. Vazquez ,  Goran Mattias Wennerstal ,  Li Xing ,  Edouard Zamaratski ,  Liying Zhang ,  Rayomand J. Unwalla

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

公开(公告)号：US10308615B2

公开(公告)日：2019-06-04

申请号：US15574625

申请日：2016-05-16

Applicant: Pfizer Inc.

Inventor： Agustin Casimiro-Garcia ,  Jeffrey Scott Condon ,  Andrew Christopher Flick ,  Ariamala Gopalsamy ,  Steven J. Kirincich ,  John Paul Mathias ,  Joseph Walter Strobach ,  Jason Shaoyun Xiang ,  Li Huang Xing ,  Xiaolun Wang

IPC: C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  A61K31/505 ,  C07D239/28 ,  C07D241/14 ,  A61P1/00 ,  A61P1/04 ,  A61P35/00 ,  C07D405/10

Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.